Sci Rep:前列腺癌中ETS转录因子ETV1和TGF-β调控的SMAD蛋白关系研究

2019-06-16 AlexYang MedSci原创

ETS转录因子ETV1在恶性前列腺癌中经常过表达,也是前列腺癌的病因之一。相应地,前列腺特异性过表达ETV1的转基因小鼠能够发生前列腺上皮内瘤样病变。然而,这些小鼠中却并不能发展为恶性肿瘤阶段,表明了抑制途径可能阻止了ETV1的完整致瘤作用。最近,有研究人员表明了TGF-β/SMAD信号就是上述的抑制途径。首先,研究人员发现ETV1能够与SMAD4形成复合物。其次,SMAD2、SMAD3和SMAD

ETS转录因子ETV1在恶性前列腺癌中经常过表达,也是前列腺癌的病因之一。相应地,前列腺特异性过表达ETV1的转基因小鼠能够发生前列腺上皮内瘤样病变。然而,这些小鼠中却并不能发展为恶性肿瘤阶段,表明了抑制途径可能阻止了ETV1的完整致瘤作用。

最近,有研究人员表明了TGF-β/SMAD信号就是上述的抑制途径。首先,研究人员发现ETV1能够与SMAD4形成复合物。其次,SMAD2、SMAD3和SMAD4过表达能够损伤ETV1促进基因转录的能力。之后,TGF-β1能够抑制良性RWPE-1前列腺细胞中ETV1诱导的侵入。最后,在ETV1转基因小鼠前列腺中能够观察到SMAD3和SMAD4表达的增加。相反,研究人员发现ETV1在PC3前列腺癌细胞中可能增强了TGF-β信号,表明了ETV1/TGF-β的相互作用的不同方面。

总之,研究人员指出,他们的数据为ETV1的调控和作用提供了新的认识,并且表明了TGF-β/SMAD信号能够通过减弱ETV1在前列腺病变部位的致瘤能力,从而来发挥其肿瘤抑制活性,并且至少是部分抑制。

原始出处:

Sangphil Oh, Sook Shin, Hoogeun Song et al. Relationship between ETS Transcription Factor ETV1 and TGF-β-regulated SMAD Proteins in Prostate Cancer. Sci Rep. 03 Jun 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2020-03-02 changhe713
  3. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2020-01-20 wshxjq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2020-02-05 mjldent
  5. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-18 江川靖瑶
  6. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1993289, encodeId=bf6b1993289a0, content=<a href='/topic/show?id=c235164347c' target=_blank style='color:#2F92EE;'>#SMAD蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16434, encryptionId=c235164347c, topicName=SMAD蛋白)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Fri May 22 08:47:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035890, encodeId=60c2203589057, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Mon Mar 02 19:47:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794150, encodeId=73bb1e94150aa, content=<a href='/topic/show?id=09e61642864' target=_blank style='color:#2F92EE;'>#Smad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16428, encryptionId=09e61642864, topicName=Smad)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 20 18:47:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747363, encodeId=69181e47363aa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Feb 05 12:47:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388903, encodeId=bb481388903b0, content=<a href='/topic/show?id=a75a1642585' target=_blank style='color:#2F92EE;'>#SMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16425, encryptionId=a75a1642585, topicName=SMA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK17mLkWpia3T92NlEWTkEhrhZa7XPNic2JqQumEicZXGYFG6Ww5SCIl0Uq62bhhPnibAqIZDHtRva92A/132, createdBy=e0752500025, createdName=江川靖瑶, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441376, encodeId=740c14413e6b5, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537490, encodeId=8a04153e49099, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Tue Jun 18 03:47:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040479, encodeId=700c10404e940, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jun 16 15:47:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-16 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Oncogene:脂多糖激活的鞘氨醇激酶能够促进前列腺癌细胞的侵入和转移

在前列腺炎和前列腺癌(PCa)组织中,主要的细菌群体是革兰氏阴性细菌,脂多糖(LPS)是革兰氏阴性细菌的重要化合物,在一些癌症类型中具有激活活性,但是到目前为止在PCa中还没有完整的研究。最近,有研究人员调查了LPS对PCa细胞入侵的影响。有趣的是,LPS能够增强PCa的侵入性,但对PCa细胞活性没有显著的影响。研究人员通过前列腺抑制剂筛选和生化分析,基质酶,一种膜锚定丝氨酸蛋白酶家族的成员,被发

PSA升高,就得了前列腺癌?

目前,在男性体检筛查中有一项重要的检查就是PSA指标。经常有人在拿到自己的体检报告的时候会有这样的疑问:tPSA和fPSA分别是什么?我的结果值高是不是就是得了前列腺癌?这fPSA/tPSA比值有啥意义? tPSA是总前列腺特异性抗原,由前列腺上皮细胞合成分泌至精液中,它只存在于人前列腺细胞中,不表达于其它细胞。正常的前列腺导管系统周围存在着屏障,避免了前列腺上皮产生的PSA直接进入血液之中

BMC Cancer:前列腺癌和小细胞癌谱系关系研究

前列腺癌具有不同的形态,而这些不同的形态可以影响患者的治疗结果。这个情况促使了人们思考分化的、可以治疗的前列腺癌与分化不良、不太可能治疗的癌症(包括小细胞癌)之间的关系以及前列腺癌分化的潜在分子机制。最近,有研究人员利用非恶性肿瘤/小细胞癌PDX LuCaP细胞系进行了干细胞转录因子(scTF)LIN28A、NANOG、POU5F1和SOX2的表达分析。研究发现,scTF在小细胞癌LuCaP 93

Radiology:用MRI指标探前列腺癌前列腺外侵犯之病理之实!

本研究旨在评价前列腺癌病理证实前列腺外侵犯(EPE)相关的MRI征象,并提出病理学EPE MRI分级系统。

Prostate Cancer P D:[68Ga] Ga-PSMA 11 PET在淋巴结中检测前列腺癌的表现研究

生化复发(BCR)前列腺癌(PCa)患者的节点复发挽救性淋巴结清扫(sLND)在当前的指南中仍旧不推荐,主要是由于当前传统成像的不准确性造成。最近,研究人员评估了[68Ga] Ga-PSMA 11 PET(PSMA-PET)在检测PCa淋巴结转移中的表现,并通过sLND进行了病理学确认。研究人员对MEDLINE、SCOPUS、Web of Science和Cochrane Library进行了搜索

Eur J Cancer Care (Engl):去势难治性前列腺癌骨转移患者中心理压力与疼痛减轻没有相关性

驱使难治性前列腺癌(CRPC)患者中,骨转移疼痛能够引起生活质量的降低(QoL)。在具有骨转移症状的CRPC患者中,镭-223治疗与良好的生存益处和骨疼痛显著减轻相关。最近,有研究人员评估了镭-223治疗期间,疼痛减轻与心理压力之间的相关性。研究总共包括了63名具有mCRPC的患者,他们均经历了镭-223治疗,并且对他们详细的说明了改善疼痛和增加生存的可能性。研究人员利用简要疼痛量表数值评定量表对